A phase 1, first-in-human, dose-escalation and biomarker trial of liposomal gemcitabine (FF-10832) in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2022 ASCO Annual ...

Figure 3. Phosphorylated p70S6K best predicted ketamine response. The phosphorylated p70S6K marker had an AUC of 0.80 (confidence interval: 0.54-0.97) for predicting ketamine response. An optimal ...

Oncotarget published "High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC" which reported that the aim of this study was therefore to define ...

Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. New soft tissue sarcoma (STS) transcriptomic clusters to ...

San Francisco–based Aeovian Pharmaceuticals has raised $37 million in series A financing to develop a small-molecule drug candidate that inhibits a protein complex called mammalian target of rapamycin ...

In a recent study published in Nature Metabolism, researchers conducted clinical studies on murine animals and humans to evaluate the impact of high protein intake on the amino acid-mammalian target ...

Researchers have identified two factors necessary for the production of memory B cells, the cells of the immune system that allow fast responses to re-infection. Without expression of the protein ...

Panel A shows how insulin and insulin-like growth factor-1 (IGF-1) effect protein anabolism by signaling through their receptors (IR and IGF1R, respectively). This signaling results in the activation ...

Researchers from the Brigham and Women’s Hospital and Harvard Medical School and collaborators recently conducted a study investigating the regulation of immune checkpoint molecules in cancer.

The mammalian target of rapamycin (mTOR) protein, a member of the phosphoinositide 3-kinase (PI3K)-related protein kinase (PIKK) family, has a central role in two growth-regulatory pathways that have ...